Article

A Call for Standardized Naming and Reporting of Human ESC and iPSC Lines

International Stem Cell Registry, Department of Cell Biology, University of Massachusetts Medical School, Shrewsbury, MA 01545, USA.
Cell stem cell (Impact Factor: 22.27). 04/2011; 8(4):357-9. DOI: 10.1016/j.stem.2011.03.002
Source: PubMed

ABSTRACT

Human embryonic and induced pluripotent stem cell lines are being generated at a rapid pace and now number in the thousands. We propose a standard nomenclature and suggest the use of a centralized database for all cell line names and a minimum set of information for reporting new derivations.

Download full-text

Full-text

Available from: Jeanne F Loring, Jan 25, 2016
  • Source
    • "Several concerted plans have been proposed that could set the stage for improving collaboration toward stem cell research goals. These integrated plans have been focused on: (1) implementing " minimum standards " for stem cell protocols and practices; (2) creating a centralized database repository with computational approaches; (3) establishing global stem cell registry information; and (4) establishing a hub for harmonizing the technical, ethical, legal, and regulatory frameworks for cell therapy products worldwide (Luong et al., 2011; Arcidiacono et al., 2012; Lowenthal et al., 2012; Turner et al., 2013; Andrews et al., 2014). However, these proposals are still under discussion and no consensus has been reached yet due to the complexity of the issues involved and the lack of organization and coordination. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver disease is a major global health concern. Liver cirrhosis is one of the leading causes of death in the world and currently the only therapeutic option for end-stage liver disease (e.g., acute liver failure, cirrhosis, chronic hepatitis, cholestatic diseases, metabolic diseases, and malignant neoplasms) is orthotropic liver transplantation. Transplantation of hepatocytes has been proposed and used as an alternative to whole organ transplant to stabilize and prolong the lives of patients in some clinical cases. Although these experimental therapies have demonstrated promising and beneficial results, their routine use remains a challenge due to the shortage of donor livers available for cell isolation, variable quality of those tissues, the potential need for lifelong immunosuppression in the transplant recipient, and high costs. Therefore, new therapeutic strategies and more reliable clinical treatments are urgently needed. Recent and continuous technological advances in the development of stem cells suggest they may be beneficial in this respect. In this review, we summarize the history of stem cell and induced pluripotent stem cell (iPSC) technology in the context of hepatic differentiation and discuss the potential applications the technology may offer for human liver disease modeling and treatment. This includes developing safer drugs and cell-based therapies to improve the outcomes of patients with currently incurable health illnesses. We also review promising advances in other disease areas to highlight how the stem cell technology could be applied to liver diseases in the future. © 2016 by John Wiley & Sons, Inc.
    Full-text · Article · Feb 2016 · Current protocols in toxicology
  • Source
    • "With a large number of patient lines and subsequent clones being generated by a number of consortia and other groups, the iPSC lines reported here will follow the naming convention recently suggested [32]. In our initial report, we generated iPSCs from fibroblasts of a type 1 spinal muscular atrophy (SMA1) patient (Coriell repository identifier: GM03813; iPSC line UW13iSMA-i.6, "
    [Show abstract] [Hide abstract]
    ABSTRACT: Spinal muscular atrophy (SMA) is a genetic disorder caused by a deletion of the survival motor neuron 1 gene leading to motor neuron loss, muscle atrophy, paralysis, and death. We show here that induced pluripotent stem cell (iPSC) lines generated from two Type I SMA subjects-one produced with lentiviral constructs and the second using a virus-free plasmid-based approach-recapitulate the disease phenotype and generate significantly fewer motor neurons at later developmental time periods in culture compared to two separate control subject iPSC lines. During motor neuron development, both SMA lines showed an increase in Fas ligand-mediated apoptosis and increased caspase-8 and-3 activation. Importantly, this could be mitigated by addition of either a Fas blocking antibody or a caspase-3 inhibitor. Together, these data further validate this human stem cell model of SMA, suggesting that specific inhibitors of apoptotic pathways may be beneficial for patients.
    Full-text · Article · Jun 2012 · PLoS ONE
  • Source
    • "Issues regarding scalability are an active area of discussion as it hinders collaboration between research groups. These issues include: reproducibility of protocols, cell line nomenclature, intellectual property issues, and lack of a detailed and centralized database of available hiPSC lines (Luong et al., 2011). There is a strong demand within the field to establish an iPSC library in conjunction with a clinical database, tissue bank, and genome wide association studies (GWAS) (Hankowski et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: An important goal of neurotoxicological research is to provide relevant and accurate risk assessment of environmental and pharmacological agents for populations and individuals. Owing to the challenges of human subject research and the real possibility of species specific toxicological responses, neuronal lineages derived from human embryonic stem cells (hESCs) and human neuronal precursors have been offered as a potential solution for validation of neurotoxicological data from model organism systems in humans. More recently, with the advent of induced pluripotent stem cell (iPSC) technology, there is now the possibility of personalized toxicological risk assessment, the ability to predict individual susceptibility to specific environmental agents, by this approach. This critical advance is widely expected to facilitate analysis of cellular physiological pathways in the context of human neurons and the underlying genetic factors that lead to disease. Thus this technology opens the opportunity, for the first time, to characterize the physiological, toxicological, pharmacological and molecular properties of living human neurons with identical genetic determinants as human patients. Furthermore, armed with a complete clinical history of the patients, human iPSC (hiPSC) studies can theoretically compare patients and at risk groups with distinct sensitivities to particular environmental agents, divergent clinical outcomes, differing co-morbidities, and so forth. Thus iPSCs and neuronal lineages derived from them may reflect the unique genetic blueprint of the individuals from which they are generated. Indeed, iPSC technology has the potential to revolutionize scientific approaches to human health. However, before this overarching goal can be reached a number of technical and theoretical challenges must be overcome. This review seeks to provide a realistic assessment of hiPSC technology and its application to risk assessment and mechanistic studies in the area of neurotoxicology. We seek to identify, prioritize, and detail the primary hurdles that need to be overcome if personalized toxicological risk assessment using patient-derived iPSCs is to succeed.
    Full-text · Article · Feb 2012 · NeuroToxicology
Show more